NCT04519918

Brief Summary

Oocyte activation is an imperative stage in the initiation of embryo development during the fertilization. Indeed, the entrance of sperm into the oocyte causes sequences of calcium oscillations in its cytoplasm, regulating a series of molecular events called oocyte activation. The intracytoplasmic sperm injection (ICSI) has allowed fertilization in couples with severe male factor infertility. But, there was still fertilization failure or low fertilization occurs in ICSI cycles. It has reported that insufficient of oocyte activation is the important cause of fertilization failure. Artificial oocyte activation (AOA) represents an effective technique, can restore the calcium oscillations to improve the fertilization. Here, the investigators explore the effective of different AOA methods including oocyte was injected CaCl2 or mechanical stimulated then treated with calcium ionophore.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 30, 2020

Completed
21 days until next milestone

First Posted

Study publicly available on registry

August 20, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

October 1, 2020

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2021

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2022

Completed
Last Updated

September 1, 2020

Status Verified

August 1, 2020

Enrollment Period

11 months

First QC Date

July 30, 2020

Last Update Submit

August 30, 2020

Conditions

Keywords

Fertilization failureArtificial Oocyte Activation (AOA)Calcium ionophoreFertilization

Outcome Measures

Primary Outcomes (1)

  • Efficacy of AOA on fertilization

    Assess the normal fertilization rate (2PN rate)

    12 months

Secondary Outcomes (2)

  • Efficacy of AOA on embryo quality

    12 months

  • Efficacy of AOA on clinical outcome

    24 months

Study Arms (3)

Standard ICSI procedure

NO INTERVENTION

a single spermatozoon was injected into the ooplasm.

Chemical oocyte activation

EXPERIMENTAL

After CaCl2 was injected, the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.

Behavioral: AOA

Mechanical oocyte activation

EXPERIMENTAL

Mechanical stimulation was done before standard ICSI procedure, then the oocytes were transferred into the calcium ionophore A23187 activation solution for two times of post-ICSI AOA.

Behavioral: AOA

Interventions

AOABEHAVIORAL

AOA represents an invasive non-physiological technique.

Chemical oocyte activationMechanical oocyte activation

Eligibility Criteria

Age22 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • The patients suffered at least one complete fertilization failure or low fertilization rate after performing standard ICSI in previous cycle. Low fertilization was defined as less than 33% fertilization rate.
  • The patients suffered at least 2 cycles complete fertilization failure or low fertilization rate after performing IVF in previous cycle. Low fertilization was defined as less than 33% fertilization rate.
  • The sperm of the patients has the following characteristics: globozoospermia, acrosomal deletion or small, severe head deformity, etc.
  • Sperm of testicular origin and/or sperm that has been freeze-thawed.
  • The sperm was PLC-ζ missing.
  • The MII oocytes were IVM cultured and/or freeze-thawed.
  • The patients suffered at least 2 cycles no available embryos, because of the embryo development block or fragmentation.

You may not qualify if:

  • Normal fertilization IVF/ICSI cycles.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tangdu Hospital

Xi'an, Shaanxi, 710038, China

Location

Study Officials

  • Li Bo, Doctor

    Reproductive Medicine Center, Tangdu Hospital

    STUDY CHAIR

Central Study Contacts

Wang Ming, Master

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 30, 2020

First Posted

August 20, 2020

Study Start

October 1, 2020

Primary Completion

August 31, 2021

Study Completion

August 31, 2022

Last Updated

September 1, 2020

Record last verified: 2020-08

Locations